HLA-G/LILRBs: A Cancer Immunotherapy Challenge

Edgardo D Carosella; Silvia Gregori; Diana Tronik-Le Roux

doi:10.1016/j.trecan.2021.01.004

HLA-G/LILRBs: A Cancer Immunotherapy Challenge

Trends Cancer. 2021 May;7(5):389-392. doi: 10.1016/j.trecan.2021.01.004. Epub 2021 Feb 6.

Authors

Edgardo D Carosella¹, Silvia Gregori², Diana Tronik-Le Roux³

Affiliations

¹ Department of Research in Hemato-Immunology, Saint-Louis Hospital, Atomic Energy and Alternative Energies Agency, Paris, France; Paris University, U976 HIPI Unit, IRSL, Paris, France.
² San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific institute, Milan, Italy.
³ Department of Research in Hemato-Immunology, Saint-Louis Hospital, Atomic Energy and Alternative Energies Agency, Paris, France; Paris University, U976 HIPI Unit, IRSL, Paris, France. Electronic address: diana.le-roux@cea.fr.

PMID: 33563576
DOI: 10.1016/j.trecan.2021.01.004

Abstract

Despite some success, many patients do not benefit from immunotherapy. New strategies to improve clinical efficacy include identification of novel immune-checkpoint (IC) targets or a combination of immunotherapy with antiangiogenic treatments. Here, we propose the therapeutic use of IC, HLA-G/LILRB, and explore its enhanced synergistic antitumor activity when combined with antiangiogenic therapies.

Keywords: HLA-G; LILRB1/2; cancer immunotherapy; immune checkpoints; vascular endothelial growth factor; vascular targeting.

MeSH terms

Angiogenesis Inhibitors / pharmacology
Angiogenesis Inhibitors / therapeutic use
Antigens, CD / metabolism*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
CD8-Positive T-Lymphocytes / drug effects
CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / metabolism
Drug Synergism
HLA-G Antigens / metabolism*
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immune Checkpoint Proteins / metabolism
Immunotherapy, Adoptive / methods*
Leukocyte Immunoglobulin-like Receptor B1 / antagonists & inhibitors
Leukocyte Immunoglobulin-like Receptor B1 / metabolism*
Lymphocytes, Tumor-Infiltrating / drug effects
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / metabolism
Membrane Glycoproteins / antagonists & inhibitors
Membrane Glycoproteins / metabolism*
Neoplasms / immunology
Neoplasms / therapy*
Receptors, Chimeric Antigen / immunology
Receptors, Immunologic / antagonists & inhibitors
Receptors, Immunologic / metabolism*
Tumor Escape
Tumor Microenvironment / drug effects
Tumor Microenvironment / immunology

Substances

Angiogenesis Inhibitors
Antigens, CD
HLA-G Antigens
Immune Checkpoint Inhibitors
Immune Checkpoint Proteins
LILRB1 protein, human
LILRB2 protein, human
Leukocyte Immunoglobulin-like Receptor B1
Membrane Glycoproteins
Receptors, Chimeric Antigen
Receptors, Immunologic